Alembic Pharmaceuticals Limited · NSE:APLLTD

Alembic Pharmaceuticals — Q4 FY21 Earnings Presentation

15 slides from Alembic Pharmaceuticals's earnings presentation, March 2021

  1. Slide 1: Alembic Pharmaceuticals Limited Investor presentation – March 2021

    Alembic Pharmaceuticals Limited Investor presentation – March 2021 BSE & NSE: APLLTD

  2. Slide 2: Milestones

    Milestones 1907 Established by Amin family 2006 FDA approves API facility 2007 Acquired Dabur’s Indian Cardiology, GI and Gynaecology brands 2008 FDA approves Formulation facility 2010 Pharmaceuticals business demerged from Alembic – APL listed 2012 Formed a JV, Rhizen, for NCE research Launched fir

  3. Slide 3: Financial Highlights

    Financial Highlights INR Bn Particulars Q4 FY21 Q4 FY20 Growth YTD FY21 YTD FY20 Growth YTD FY20 Net Sales 12.80 12.07 6% 53.93 46.06 17% 46.06 EBIDTA Pre R&D 5.40 5.12 5% 22.52 18.15 24% 18.15 Margin % 42% 42% 42% 39% 39% R&D 1.95 1.85 5% 6.70 6.45 4% 6.45 R&D % 15% 15% 12% 14% 14% EBIDTA Post R&D

  4. Slide 4: Business snapshot – Q4FY21

    Business snapshot – Q4FY21 Formulations Generics Branded API Total US Ex-US India Revenue Q4FY21 (INR Bn) 4.75 2.33 3.58 2.14 12.80 API Vet 17% 17% 37% 4% Generics Q4FY21 Revenue Acute 55% Contribution 7% Branded 28% 18% Speciality 17% Growth Q4FY21 -18% 77% 5% 38% 6% over Q4FY20 Growth Q4FY21 -7% -

  5. Slide 5: Business snapshot – YTDFY21

    Business snapshot – YTDFY21 Formulations Generics Branded API Total US Ex-US India Revenue YTDFY21 (INR Bn) 21.63 7.79 14.97 9.55 53.93 API Vet 18% 18% 3% YTDFY21 Revenue 40% Generics Acute 55% Contribution 9% Branded Speciality 16% 28% 14% Growth YTDFY21 9% 57% 5% 35% 17% over YTDFY20 • Well-establ

  6. Slide 6: US Generic

    US Generic INR Bn Revenue – Q4 FY21 INR Bn Revenue – Last 5 Years CAGR - 24% 19.76 21.63 5.77 4.75 12.88 9.19 9.20 Q4FY20 Q4FY21 FY17 FY18 FY19 FY20 FY21 Approved ANDAs Derma Injectable 1 14 ➢ Well-established US front end having strong customer base Ophthalmic 13 ➢ Expanded our capabilities to deli

  7. Slide 7: Ex-US Generics

    Ex-US Generics Revenue : Q4 FY21 INR Bn Revenue – Last 5 Years INR Bn 2.33 CAGR - 25% 7.79 1.32 4.94 4.97 Q4FY20 Q4FY21 ➢ Ex-US driven by partnership 3.20 2.86 ➢ Presence in following markets - Europe, Canada, Australia, Brazil and South Africa ➢ The business will focus on new launches across key ma

  8. Slide 8: API

    API Revenue : Q4 FY21 INR Bn Revenue – Last 5 Years INR Bn CAGR - 11% 2.14 9.55 1.55 7.71 7.08 6.40 6.51 Q4FY20 Q4FY21 ➢ Sales across geographies as preferred supplier ➢ Investing in plants to create additional capacities ➢ FDA Compliant plants ➢ State of the art R&D center and Process development l

  9. Slide 9: R&D Significant investments in building capabilities

    R&D Significant 10.0 investments in building capabilities INR Bn ANDA – Accelerated filings & approvals 37 Filing 8.0 13.7% 14.0% Approval 13.1% 12.7% 29 30 29 12.4% 6.0 25 R&D Spend 20 19 20 18 * 11 Filings & 4.0 6.7 7 Approvals 6.5 R&D % of were 5.0 sales 2.0 4.3 4.1 contributed by 5 acquisition o

  10. Slide 10: State of the art facilities and infrastructure

    State of the art facilities and infrastructure Audit/Filing Location Dosage Form status International Generics F1 – Panelav General Oral Solids Mar’20* Oncology Oral Solids Jun’19* F2 – Panelav Oncology Injectables Feb’21# F2 - Panelav F3 - Karkhadi General Injectables F3 – Karkhadi Ophthalmic Feb’2

  11. Slide 11: Branded Business

    Branded Business Revenue – Q4 FY21 INR Bn Revenue – Last 5 Years CAGR - 5% INR Bn 15.0 13.8 14.3 3.42 3.58 12.5 12.7 0.29 0.45 Vet 1.32 0.94 Acute Speciality 1.81 2.19 Q4FY20 Q4FY21 FY17 FY18 FY19 FY20 FY21 Marketing organization Key achievements ➢ 5000 + Marketing team ➢ 2 Brands in top 300 ➢ 17 Ma

  12. Slide 12: Therapy-wise Performance Q4 FY21

    Therapy-wise Performance Q4 FY21 Q4 FY21 Q4 FY20 Therapy Market Alembic Alembic Therapy Market Alembic Alembic Therapy (%) Growth Share % Growth % Growth % Growth Share Growth % Growth % % (ORG) (ORG) (ORG) (PRIM) % (ORG) % (ORG) (ORG) (PRIM) Cardiology 10 1.9 13 9 15 1.9 12 20 Gynecology 15 2.8 33

  13. Slide 13: Therapy-wise Performance YTD FY21

    Therapy-wise Performance YTD FY21 YTD FY21 YTD FY20 Therapy Market Alembic Alembic Therapy Market Alembic Alembic Therapy (%) Growth Share % Growth % Growth % Growth Share Growth % Growth % % (ORG) (ORG) (ORG) (PRIM) % (ORG) % (ORG) (ORG) (PRIM) Cardiology 13 1.9 14 15 12 1.9 7 7 Gynecology 3 2.7 10

  14. Slide 14: Financials : Generating consistent returns

    Financials : Generating consistent returns Revenue INR Bn EBIDTA Net Profit INR Bn INR Bn 53.93 16.31 11.78 46.06 39.35 12.13 8.29 31.34 31.31 8.75 5.84 6.15 6.42 4.13 4.03 FY17 FY18 FY19 FY20 FY21 FY17 FY18 FY19 FY20 FY21 FY17 FY18 FY19 FY20 FY21 CAGR - 15% CAGR - 28% CAGR - 31% EBIDTA margin % Cap

  15. Slide 15: Thank you

    Thank you Safe Harbour Agreement: Materials and information provided during this presentation may contain ‘forward-looking statements’. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties which could cause actual outcomes and resu

Alembic Pharmaceuticals — Q4 FY21 Earnings Presentation on 6ix